Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar-Reference-Cited by-同舟云学术

Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar

Published:2023-09-25 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Randrianarisoa Rova Malala Fandresena¹^ORCID,Refeno Valéry²,Andrianandrasana Ny Ony Tiana Florence³,Ralison Fidiarivony⁴,Vololontiana Hanta Marie Danielle¹,Rafaramino Florine⁵

Affiliation:

1. Department of Internal Medicine, Joseph Raseta Befelatanana Hospital, Antananarivo, Madagascar

2. Oncology Department, Professeur Zafisaona Gabriel Hospital, Mahajanga, Madagascar

3. Oncology Department, Joseph Ravoahangy Andrianavalona Hospital, Antananarivo, Madagascar

4. Department of Internal Medicine, Mahavoky Atsimo Hospital, Mahajanga, Madagascar

5. Faculty of Medicine, Antananarivo, Madagascar

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2261803

Reference29 articles.

1. Multiple myeloma epidemiology and survival: A unique malignancy

2. The Global Cancer Observatory. Multiple myeloma – GLOBOCAN 2020. [fact-sheets] [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf

3. The Global Cancer Observatory. United States of America – GLOBOCAN 2020 [fact-sheets]. [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf

4. The Global Cancer Observatory. France – GLOBOCAN 2020 [fact-sheets]. [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/250-france-fact-sheets.pdf

5. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial